517,426 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. bought a new position in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 517,426 shares of the company's stock, valued at approximately $1,599,000. Jacobs Levy Equity Management Inc. owned about 0.48% of Tango Therapeutics at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the company. Graham Capital Management L.P. purchased a new stake in Tango Therapeutics in the fourth quarter worth $108,000. Ensign Peak Advisors Inc increased its position in Tango Therapeutics by 100.3% in the fourth quarter. Ensign Peak Advisors Inc now owns 57,319 shares of the company's stock worth $177,000 after buying an additional 28,700 shares during the last quarter. Farallon Capital Management LLC purchased a new position in shares of Tango Therapeutics in the fourth quarter valued at $12,360,000. Deutsche Bank AG grew its position in shares of Tango Therapeutics by 24.1% in the fourth quarter. Deutsche Bank AG now owns 36,653 shares of the company's stock valued at $113,000 after purchasing an additional 7,128 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. purchased a new position in shares of Tango Therapeutics in the fourth quarter valued at $355,000. 78.99% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and issued a $13.00 price target on shares of Tango Therapeutics in a research report on Monday, April 14th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $12.33.

Tango Therapeutics Trading Down 1.9%

Shares of NASDAQ TNGX traded down $0.04 during mid-day trading on Thursday, hitting $1.86. The company had a trading volume of 625,583 shares, compared to its average volume of 1,247,483. The company has a market capitalization of $201.07 million, a price-to-earnings ratio of -1.57 and a beta of 1.02. Tango Therapeutics, Inc. has a 1 year low of $1.03 and a 1 year high of $12.02. The stock's 50-day moving average price is $1.46 and its 200-day moving average price is $2.48.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.02). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The company had revenue of $5.39 million during the quarter, compared to analysts' expectations of $6.73 million. As a group, equities research analysts forecast that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current year.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.